Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma-Reference-Cited by-同舟云学术

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma

Published:2015-05-01 Issue:2 Volume:7 Page:86-88
ISSN:2036-3613
Container-title:Rare Tumors
language:en
Short-container-title:Rare Tumors

Author:

Attia Steven¹,Okuno Scott H.²,Robinson Steven I.²,Webber Nicholas P.³,Indelicato Daniel J.⁴,Jones Robin L.⁵,Bagaria Sanjay P.⁵,Jones Robin L.¹,Sherman Courtney¹,Kozak Kevin R.⁶,Cortese Cherise M.¹,McFarland Thomas⁷,Trent Jonathan C.⁸,Maki Robert G.⁹

Affiliation:

1. Mayo Clinic, Jacksonville, FL, USA

2. Mayo Clinic, Rochester, MN, USA

3. 3Aurora Healthcare, Milwaukee, WI, USA

4. 4University of Florida, Jacksonville, FL, USA

5. Royal Marsden Hospital, London, UK

6. Mercy Medical Center, Janesville, WI, USA

7. University of Wisconsin, Madison, WI, USA

8. University of Miami, FL, USA

9. Mount Sinai Medical Center, New York, NY, USA

Abstract

We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.

Publisher

SAGE Publications

Subject

Oncology,Histology

Link

http://journals.sagepub.com/doi/pdf/10.4081/rt.2015.5992

Reference11 articles.

1. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints

2. Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing’s Sarcoma Study Group

3. Clinical features and outcomes in patients with extraskeletal ewing sarcoma

4. Past failures and future possibilities in Ewing's sarcoma:Experimental and preliminary clinical results

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological and molecular genetic analysis of 13 cases of primary retroperitoneal Ewing sarcoma;Annals of Diagnostic Pathology;2024-10

2. Cushing's syndrome caused by giant Ewing's sarcoma of the kidney: A case report and review of literature;World Journal of Clinical Cases;2024-08-16

3. Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma;Oncoscience;2023-09-20

4. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma;Frontiers in Oncology;2023-03-13

5. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results;Cancer Medicine;2022-08-10